Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Jul 2, 2012
Clinical News
Lyme disease Line Immunoassay regulatory update
...antigens that serve as markers for general infection and for specific stages of the disease.
Gold Standard Diagnostics Inc.
...
Read More
BioCentury
|
Dec 12, 2011
Company News
Axis-Shield, Gold Standard Diagnostics sales and marketing update
...in human serum or plasma. Details were not disclosed. Axis-Shield plc (LSE:ASD; OSE:ASD), Dundee, U.K.
Gold Standard Diagnostics Inc.
...
Read More
BioCentury
|
Mar 8, 2010
Financial News
Gold Standard Diagnostics completes venture financing
Gold Standard Diagnostics Inc.
, Davis, Calif. Business: Diagnostic Date completed: 3/2/10 Type: Venture financing Raised: Undisclosed Investors: Private investors WIR Staff...
Read More
Items per page:
10
1 - 3 of 3
BioCentury
|
Jul 2, 2012
Clinical News
Lyme disease Line Immunoassay regulatory update
...antigens that serve as markers for general infection and for specific stages of the disease.
Gold Standard Diagnostics Inc.
...
Read More
BioCentury
|
Dec 12, 2011
Company News
Axis-Shield, Gold Standard Diagnostics sales and marketing update
...in human serum or plasma. Details were not disclosed. Axis-Shield plc (LSE:ASD; OSE:ASD), Dundee, U.K.
Gold Standard Diagnostics Inc.
...
Read More
BioCentury
|
Mar 8, 2010
Financial News
Gold Standard Diagnostics completes venture financing
Gold Standard Diagnostics Inc.
, Davis, Calif. Business: Diagnostic Date completed: 3/2/10 Type: Venture financing Raised: Undisclosed Investors: Private investors WIR Staff...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page